Vancomycin Resistant Staphylococcus Aureus Infection Market Projected to Gain Significant Value by 2024

Staphylococcus aureus is an anaerobic gram positive bacteria, commonly found in the respiratory tract of human and on the skin. This strain of bacteria is always not pathogenic but remains a major cause for respiratory diseases, skin infections and food poisoning. S.aureus strains often promote infections by producing harmful protein toxins. It is anticipated that approximately 20% of the population carries S.aureus in the anterior part of nasal passages and in the skin flora. Among all the strains of staphylococcus, S.aureus is one of the most common species that cause Staph infection and cause range of illness such as impetigo, boils, pimples, skin infections, abscesses and other life threatening diseases such as meningitis, pneumonia, sepsis, osteomyelitis and others.

View Report -

https://www.transparencymarketresearch.com/vancomycin-resistant-staphylococcus-aureus-infection-market.html

S.aureus infection remains one of the most common causes of postsurgical wound infection and nosocomial infections. Penicillin is the most common choice witnessed for the treatment of S.aureus infection but development of resistance from penicillin is commonly seen hence, a combination therapy along with gentamicin is prescribed for the treatment of infections. In addition, currently some of the strains have developed resistance to B-Lactam antibiotics which are termed as Methicillin resistant S.aureus (MRSA). This type of infection is growing at a rapid rate and is most often found in hospitals, clinics and in community regions.

Likewise, vancomycin resistant Staphylococcus aureus refers to the strains of S.aureus that have become resistant antibiotic glycopeptides (vancomycin). Presently three classes of vancomycin-resistant S.aureus (VRSA) have emerged namely high level VRSA, vancomycin-intermediate S.aureus (VISA) and heterogenus VISA (hVISA). VISA infection was firstly identified in Japanese hospitals however, later this strain of bacteria is also found in the Asian region. Linezolid, Ceftobiprole, daptomycin, tigercycline and others are the major drugs prescribed for the treatment of VISA infection. VRSA infection usually reported in people having weakened immune system or to those who are taking vancomycin for a longer duration. The infection is also seen in those people who have undergone surgical procedures.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17336

The vancomycin resistant staphylococcus aureus infection market is increasing due to rising incidences of the infection. Additionally, growth in government and non government awareness program are also other major factors that are expected to drive the growth of this market. For instance, Centers for Disease Control and Prevention is constantly working with the healthcare facilities, state local health agencies and clinical microbiology agencies. VRSA infections can be treated with various commercially available antibiotics however, most efficient way of controlling the spread of VRSA is maintaining basic hygienic conditions such as proper wound care, washing hands before while contacting directly with the patients and use of disposable gloves.

Geographically, North America and Europe dominates the vancomycin resistant Staphylococcus Aureus market due to rising incidences of VRSA incidences and demand for new innovative drugs. However, during the forecast period these regions are expected to show slow growth due to market maturity, shortened drug lifecycle and generic infiltration. Asia-pacific region is anticipated to emerge as the fastest growing region in the near future due to growing number of pharmaceutical manufacturers in the Asian countries and also due to the presence of some of the world’s leading generics manufacturers in this region.